SK51199A3 - Polypeptides comprising gax protein domains, involved in repressing transcription and/or interacting with other proteins, corresponding nucleic acids and their use - Google Patents
Polypeptides comprising gax protein domains, involved in repressing transcription and/or interacting with other proteins, corresponding nucleic acids and their use Download PDFInfo
- Publication number
- SK51199A3 SK51199A3 SK511-99A SK51199A SK51199A3 SK 51199 A3 SK51199 A3 SK 51199A3 SK 51199 A SK51199 A SK 51199A SK 51199 A3 SK51199 A3 SK 51199A3
- Authority
- SK
- Slovakia
- Prior art keywords
- gax
- protein
- polypeptide
- dna
- fragment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/788—Of specified organic or carbon-based composition
- Y10S977/797—Lipid particle
- Y10S977/798—Lipid particle having internalized material
- Y10S977/799—Containing biological material
- Y10S977/80—Nucleic acid, e.g. DNA or RNA
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/915—Therapeutic or pharmaceutical composition
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9612730A FR2754822B1 (fr) | 1996-10-18 | 1996-10-18 | Polypeptides comprenant des domaines de la proteine gax, impliques dans la repression de transcription et/ou interagissant avec d'autres proteines, acides nucleiques correspondants et leurs utilisations |
| PCT/FR1997/001850 WO1998017686A1 (fr) | 1996-10-18 | 1997-10-16 | Polypeptides comprenant des domaines de la proteine gax, impliques dans la repression de transcription et/ou interagissant avec d'autres proteines, acides nucleiques correspondants et leurs utilisations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SK51199A3 true SK51199A3 (en) | 2000-04-10 |
Family
ID=9496803
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK511-99A SK51199A3 (en) | 1996-10-18 | 1997-10-16 | Polypeptides comprising gax protein domains, involved in repressing transcription and/or interacting with other proteins, corresponding nucleic acids and their use |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US6121005A (fr) |
| EP (1) | EP0941243A1 (fr) |
| JP (1) | JP2001503615A (fr) |
| KR (1) | KR20000049249A (fr) |
| CN (1) | CN1237980A (fr) |
| AP (1) | AP9901510A0 (fr) |
| AU (1) | AU741586B2 (fr) |
| BG (1) | BG63548B1 (fr) |
| BR (1) | BR9711947A (fr) |
| CA (1) | CA2268045A1 (fr) |
| CZ (1) | CZ131899A3 (fr) |
| EA (1) | EA003694B1 (fr) |
| FR (1) | FR2754822B1 (fr) |
| HU (1) | HUP9903956A3 (fr) |
| IL (1) | IL129478A0 (fr) |
| NO (1) | NO991830L (fr) |
| NZ (1) | NZ335283A (fr) |
| OA (1) | OA11034A (fr) |
| PL (1) | PL332874A1 (fr) |
| SK (1) | SK51199A3 (fr) |
| WO (1) | WO1998017686A1 (fr) |
| ZA (1) | ZA979390B (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001289652A1 (en) * | 2000-06-28 | 2002-01-08 | Aventis Pharma S.A. | Compositions and methods for regulating the cell cycle using a ki gene or polypeptide |
| US8124598B2 (en) | 2006-09-14 | 2012-02-28 | Sharon Sageman | 7-keto DHEA for psychiatric use |
| US20100160274A1 (en) * | 2007-09-07 | 2010-06-24 | Sharon Sageman | 7-KETO DHEA for Psychiatric Use |
| US20130059773A1 (en) * | 2010-02-24 | 2013-03-07 | Veronique Witko-Sarsat | Compounds for the treatment of inflammation and neutropenia |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5856121A (en) * | 1994-02-24 | 1999-01-05 | Case Western Reserve University | Growth arrest homebox gene |
| US5554181A (en) * | 1994-05-04 | 1996-09-10 | Regents Of The University Of Minnesota | Stent |
| GB9422175D0 (en) * | 1994-11-03 | 1994-12-21 | Univ Dundee | Indentification of the p21 waf1-pcna interaction site and therapeutic applications thereof |
| FR2732357B1 (fr) * | 1995-03-31 | 1997-04-30 | Rhone Poulenc Rorer Sa | Vecteurs viraux et utilisation pour le traitement des desordres hyperproliferatifs, notamment de la restenose |
| FR2740344B1 (fr) * | 1995-10-31 | 1997-11-21 | Rhone Poulenc Rorer Sa | Application de la proteine gax au traitement de cancers |
-
1996
- 1996-10-18 FR FR9612730A patent/FR2754822B1/fr not_active Expired - Fee Related
-
1997
- 1997-10-15 US US08/950,860 patent/US6121005A/en not_active Expired - Fee Related
- 1997-10-16 EA EA199900387A patent/EA003694B1/ru not_active IP Right Cessation
- 1997-10-16 KR KR1019990703354A patent/KR20000049249A/ko not_active Application Discontinuation
- 1997-10-16 IL IL12947897A patent/IL129478A0/xx unknown
- 1997-10-16 BR BR9711947A patent/BR9711947A/pt not_active Application Discontinuation
- 1997-10-16 EP EP97911277A patent/EP0941243A1/fr not_active Withdrawn
- 1997-10-16 CA CA002268045A patent/CA2268045A1/fr not_active Abandoned
- 1997-10-16 HU HU9903956A patent/HUP9903956A3/hu unknown
- 1997-10-16 AU AU48713/97A patent/AU741586B2/en not_active Ceased
- 1997-10-16 CZ CZ991318A patent/CZ131899A3/cs unknown
- 1997-10-16 NZ NZ335283A patent/NZ335283A/en unknown
- 1997-10-16 PL PL97332874A patent/PL332874A1/xx unknown
- 1997-10-16 WO PCT/FR1997/001850 patent/WO1998017686A1/fr not_active Application Discontinuation
- 1997-10-16 AP APAP/P/1999/001510A patent/AP9901510A0/en unknown
- 1997-10-16 JP JP51902498A patent/JP2001503615A/ja active Pending
- 1997-10-16 SK SK511-99A patent/SK51199A3/sk unknown
- 1997-10-16 CN CN97199823A patent/CN1237980A/zh active Pending
- 1997-10-20 ZA ZA9709390A patent/ZA979390B/xx unknown
-
1999
- 1999-04-16 BG BG103342A patent/BG63548B1/bg unknown
- 1999-04-16 NO NO991830A patent/NO991830L/no not_active Application Discontinuation
- 1999-04-16 OA OA9900083A patent/OA11034A/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA199900387A1 (ru) | 1999-10-28 |
| CA2268045A1 (fr) | 1998-04-30 |
| NO991830D0 (no) | 1999-04-16 |
| BG63548B1 (bg) | 2002-04-30 |
| WO1998017686A1 (fr) | 1998-04-30 |
| EP0941243A1 (fr) | 1999-09-15 |
| FR2754822B1 (fr) | 1998-11-27 |
| FR2754822A1 (fr) | 1998-04-24 |
| JP2001503615A (ja) | 2001-03-21 |
| IL129478A0 (en) | 2000-02-29 |
| CZ131899A3 (cs) | 1999-07-14 |
| HUP9903956A2 (hu) | 2000-03-28 |
| PL332874A1 (en) | 1999-10-25 |
| AU741586B2 (en) | 2001-12-06 |
| AU4871397A (en) | 1998-05-15 |
| KR20000049249A (ko) | 2000-07-25 |
| NZ335283A (en) | 2001-02-23 |
| ZA979390B (en) | 1998-05-12 |
| AP9901510A0 (en) | 1999-06-30 |
| NO991830L (no) | 1999-06-16 |
| HUP9903956A3 (en) | 2002-01-28 |
| US6121005A (en) | 2000-09-19 |
| EA003694B1 (ru) | 2003-08-28 |
| OA11034A (fr) | 2003-03-06 |
| CN1237980A (zh) | 1999-12-08 |
| BR9711947A (pt) | 1999-08-24 |
| BG103342A (en) | 2000-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2340328C (fr) | Facteur-1 alpha stable inductible en hypoxie et procede d'utilisation | |
| CZ308897A3 (cs) | Virové vektory a jejich použití pro léčení hyperprofilerativních nemocí, zejména restenosy | |
| US6933373B2 (en) | P53 protein variants and therapeutic uses thereof | |
| EP0938553B1 (fr) | Adn codant dp-75 et procede d'utilisation | |
| TW496873B (en) | Bispecific chimeric molecule, nucleic acid sequence thereof, and in vitro expression system containing the same | |
| CZ145599A3 (cs) | Způsob obnovení translační aktivity závislé na p53 v buňkách, jednořetězcové protilátky proti p53 a DNA, které je kódují, jejich použití a prostředky, které je obsahují | |
| SK51199A3 (en) | Polypeptides comprising gax protein domains, involved in repressing transcription and/or interacting with other proteins, corresponding nucleic acids and their use | |
| EP0846761A1 (fr) | Nouveau facteur de transcription exprimé dans des cellules en phase cyclique, molécules d'acides nucléiques codant pour ce facteur de transcription et sa régionpromotrice et utilisations de ceux-ci | |
| US6544948B1 (en) | ΔP62, variants thereof, amino acid sequences coding therefor and their uses in gene therapy for cancer | |
| WO1998019686A1 (fr) | Methodes therapeutiques pour lesion vasculaire | |
| WO1998019686A9 (fr) | Methodes therapeutiques pour lesion vasculaire | |
| MXPA99003470A (en) | Polypeptides comprising gax protein domains, involved in repressing transcription and/or interacting with other proteins, corresponding nucleic acids and their use | |
| JP2002509433A (ja) | 心筋および骨格筋に特異的な核酸、ならびにその製造方法および使用 | |
| WO2001018036A2 (fr) | Methodes et reactifs permettant de reguler l'expression genique | |
| JPH0866192A (ja) | ヒトｓ−Ｍｙｃ様ポリペプチド及びそれをコードする遺伝子 | |
| Clair | The dual specificity phosphatase Cdc25C is transcriptionally repressed by the tumor suppressor protein p53 | |
| MXPA97006928A (es) | Sistema de expresion condicional | |
| WO2002094307A1 (fr) | Yin yang-1 | |
| MXPA97008877A (en) | P62, its variants, the nucleic acid sequences that code them, and its use in anti-cancer gene therapy | |
| AU2002308413A1 (en) | Yin yang 1 |